Taffic Tablet

• Treatment of Human immunodeficiency virus 1 (HIV-1) Infection

Like most antiviral drugs, Taffic Tablet   may cause some adverse effects on the body during the treatment. These can vary from mild to severe depending on the dose and the patient’s health condition.

Common side effects include:

• Depression
• Abnormal dreams
• Headache
• Dizziness
• Diarrhea
• Feeling sick (Nausea)
• Tiredness (Fatigue)

Serious

• Worsening of Hepatitis B
• Kidney injury
• Immune reconstitution syndrome
• Lactic acidosis

Inform your doctor immediately if you experience any persistent or unusual side effects.

• Doctor determines the exact dose and duration with Taffic Tablet as per the overall health condition of the patient. This capsule should be taken with food or after food, but at the fix time every day to get effective results.
• Don't miss a dose or overdose on the medicine. Swallow it as a whole with a glass of water and do not crush, chew, or open it.​​
  

• Taffic Tablet is an antiretroviral drugs with the combination of tenofovir alfenamide, emtricitabine, and bictegravir. They function by preventing the human immunodeficiency virus from multiplying, which reduces the infection's level in your body.
• Additionally, they raise the number of CD4 cells in your blood, which are white blood cells that fight infection.​
  

• Squillace, N., Ricci, E., Maggi, P., Taramasso, L., Menzaghi, B., De Socio, G. V., ... & CISAI Study Group. (2023). Real-life safety of emtricitabine/tenofovir alafenamide/bictegravir. PLoS One, 18(8), e0289132. https://pubmed.ncbi.nlm.nih.gov/37556481/
• Avihingsanon, A., Lu, H., Leong, C. L., Hung, C. C., Koenig, E., Kiertiburanakul, S., ... & Li, T. (2023). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. The Lancet HIV, 10(10), e640-e652. https://pubmed.ncbi.nlm.nih.gov/37494942/
• Sax, P. E., Arribas, J. R., Orkin, C., Lazzarin, A., Pozniak, A., DeJesus, E., ... & Wohl, D. (2023). Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine, 59. https://pubmed.ncbi.nlm.nih.gov/37200995/
• Sax, P. E., Rockstroh, J. K., Luetkemeyer, A. F., Yazdanpanah, Y., Ward, D., Trottier, B., ... & GS-US-380–4030 Investigators. (2021). Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clinical Infectious Diseases, 73(2), e485-e493. https://pubmed.ncbi.nlm.nih.gov/32668455/
• Ambrosioni, J., Rojas Liévano, J., Berrocal, L., Inciarte, A., de la Mora, L., González-Cordón, A., ... & Mallolas, J. (2022). Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. Journal of Antimicrobial Chemotherapy, 77(4), 1133-1139.
• Deeks, E. D. (2018). Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection: ED Deeks. Drugs, 78(17), 1817-1828. https://pubmed.ncbi.nlm.nih.gov/30460547/